Easterly Investment Partners LLC Buys 39,014 Shares of Becton, Dickinson and Company $BDX

Easterly Investment Partners LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 264.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,783 shares of the medical instruments supplier’s stock after acquiring an additional 39,014 shares during the quarter. Easterly Investment Partners LLC’s holdings in Becton, Dickinson and Company were worth $10,438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after purchasing an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in Becton, Dickinson and Company by 88.2% in the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares in the last quarter. Assetmark Inc. increased its holdings in Becton, Dickinson and Company by 49.5% in the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock worth $42,294,000 after purchasing an additional 74,795 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 0.5% in the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after purchasing an additional 147,041 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.0%

Shares of Becton, Dickinson and Company stock opened at $147.13 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a 50 day moving average price of $151.63 and a two-hundred day moving average price of $176.99. The stock has a market capitalization of $40.54 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter last year, the firm posted $3.35 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Jefferies Financial Group lowered their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Citigroup lowered their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a report on Tuesday, April 14th. Evercore lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Finally, Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.